HemaSphere (Jun 2022)

PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT

  • L. Faulkner,
  • M. Garg,
  • C. Suresh

DOI
https://doi.org/10.1097/01.HS9.0000850824.39215.bd
Journal volume & issue
Vol. 6
pp. 1869 – 1870

Abstract

Read online

No abstracts available.